DepYmed develops potent inhibitors of the enzyme PTP1B to target cancer and rare diseases, including Rett Syndrome and Wilson Disease. The company is advancing orally bioavailable small molecules into clinical trials to address the underlying signaling pathway disruptions caused by protein tyrosine phosphatases.
Funding
$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Protein tyrosine phosphatases (PTPs) are key signaling enzymes implicated in the pathology of various diseases, including cancers, rare diseases, and metabolic, inflammatory, and neurodegenerative disorders. Selectively targeting these enzymes with small molecule inhibitors has been challenging. Current treatment options for diseases like Rett Syndrome and Wilson Disease have limitations in addressing the underlying signaling pathway disruptions.
Solution
DepYmed is developing orally bioavailable small molecule inhibitors targeting PTP1B, a specific PTP enzyme, for the treatment of cancer and rare diseases. The company's lead program focuses on advancing these inhibitors into clinical trials for Rett Syndrome, Wilson Disease, and certain cancers. In addition, DepYmed has a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. These molecules aim to modulate signaling pathways involved in disease progression, offering a potential therapeutic intervention.
Target Audience
The primary target audience includes patients suffering from Rett Syndrome, Wilson Disease, and specific cancers, as well as pharmaceutical companies seeking novel therapeutics for these conditions.
Features
- Orally bioavailable small molecule PTP1B inhibitors
- Copper-chelating small molecules for Wilson Disease and cancer
- Selective targeting of protein tyrosine phosphatases
- Lead program: DPM-1003, a PTP1B inhibitor in Phase 1 clinical trials for Rett Syndrome
- Potential application in oncology, metabolic, inflammatory, and neurodegenerative diseases